← CNNC Hua Yuan Titanium Dioxide overview

CNNC Hua Yuan Titanium Dioxide vs BASF: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

CNNC Hua Yuan Titanium Dioxide Co Ltd (002145.CS)

BASF SE (BAS.XETRA)

Q3 202630 Jun – 25 Sep 2026

▲2▼1

BASF's mixed Q3: asset sale, buyback, AI bet, but Rhine and EU risks

Coatings sale completed BASF finished selling its coatings business to Carlyle for €7.7bn, boosting cash, profit, and earnings per share while keeping a 40% stake. This strengthens the balance sheet and supports shareholder returns.
Major completed deal that directly improved financials and cash flow.
AI investment and buyback BASF invested $1.1bn in AI for medical plastics and started a €1bn share buyback. These moves aim to drive future growth and return cash to shareholders, signaling confidence.
New strategic investments and capital returns that could lift investor sentiment.
Rhine water and EU emissions risks Record-low Rhine water levels threaten production and raw-material supplies, while an EU emissions overhaul could raise costs. These factors create operational and regulatory uncertainty.
Key external risks that could disrupt operations and increase expenses.
Evonik takeover talks BASF proposed a €12bn takeover of Evonik, which could create a European chemicals giant, but talks are early and shares fell nearly 2% on integration and funding concerns.
Potential transformative deal with uncertain outcome and negative initial market reaction.

August 202629 Jul – 25 Sep 2026

▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.
This is the period's biggest positive fundamental news and directly supports the share price.
Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.
It shows a broad industry pricing upturn that directly benefits BASF's earnings.
Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.
This is a real operational risk that could hurt earnings and weigh on the stock.
Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.
This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

Latest29 Jul – 25 Sep 2026

▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.
This is the period's biggest positive fundamental news and directly supports the share price.
Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.
It shows a broad industry pricing upturn that directly benefits BASF's earnings.
Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.
This is a real operational risk that could hurt earnings and weigh on the stock.
Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.
This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

July 202630 Jun – 17 Jul 2026

▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.
This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.
New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.
A concrete new product launch that supports future revenue growth in a profitable segment.
AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.
Shows BASF investing in technology that may improve margins and competitiveness over time.
EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.
A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.

30 Jun – 17 Jul 2026

▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.
This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.
New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.
A concrete new product launch that supports future revenue growth in a profitable segment.
AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.
Shows BASF investing in technology that may improve margins and competitiveness over time.
EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.
A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.